Search

News Prediction of Ischemic Stroke Risk in Patients with Rheumatoid Arthritis Using a Simplified Score

Ischemic strokes (iCMP) are a common cause of death or significant disability in developed countries. Patients with rheumatoid arthritis (RA) are affected by them even more frequently than the general population. A newly developed scoring system is capable of predicting the risk of iCMP in these patients.

Source: Arthritis 3. 12. 2020

News Bimekizumab vs. Adalimumab in the Treatment of Moderate to Severe Plaque Psoriasis

Bimekizumab is a humanized IgG1 monoclonal antibody that selectively inhibits interleukins 17A and 17F for the treatment of moderate to severe plaque psoriasis in adults for whom systemic therapy is indicated. The phase III BE SURE clinical trial focused on comparing the efficacy and safety of bimekizumab and the tumor necrosis factor-alpha (TNF-α) inhibitor adalimumab, which currently serves as one of the mainstays of systemic therapy.

Source: Psoriasis 12. 9. 2022

News Analysis of the Benefits and Risks of Superabsorbent Dressings in the Treatment of Moderate to Highly Exuding Leg Ulcers

A study on the benefits and risks of superabsorbent dressings compared to standard dressings in the treatment of moderate to highly exuding leg ulcers was published last year in The International Journal of Lower Extremity Wounds.

Source: Wound Healing 22. 2. 2022

News Under the Microscope: How is Patient Care for Heart Failure in the Czech Republic in Real Practice?

The journal Vnitřní lékařství recently published the results of a survey conducted among outpatient cardiologists and internists. The aim was to determine the level of diagnosis and treatment of patients with chronic heart failure (CHF) in real-life practice in the Czech Republic, with a special focus on the presence of symptoms in patients who have not yet been diagnosed. We briefly summarize the key findings from this survey.

Source: Heart Failure 18. 4. 2024

News Diagnosis of AHA Requires Laboratory Testing –⁠ What Are Its Key Specifics?

Acquired hemophilia A (AHA) is a rare but very serious disease with a high mortality rate. Quick and accurate diagnosis is crucial, but according to RNDr. Ingrid Hrachovinová, Ph.D., from the Institute of Hematology and Blood Transfusion in Prague (ÚHKT), it requires sufficient information and experience. In her lecture on this topic at the XXVIII. Czech-Slovak Conference on Thrombosis and Hemostasis held together with the XX. Czech-Slovak Conference on Laboratory Hematology in mid-September in Hradec Králové, she provided a number of useful guidelines for practice.

Source: Acquired Hemophilia 14. 10. 2022

News What Results Does Bimekizumab Achieve in Patients with PsA After 3 Years of Treatment?

Fresh findings from the BE ACTIVE study were published this year in the journal Rheumatology, which evaluated the effects of long-term treatment of individuals with psoriatic arthritis (PsA) with bimekizumab in terms of patient-reported outcomes (PROs).

Source: Psoriasis 10. 8. 2023

News INFOGRAPHIC: How does liposomal ozonized oil work in treating eye infections?

Ozonized sunflower oil exhibits antimicrobial, anti-inflammatory, and healing properties, which is why it is added to eye drops intended for infection prevention. We bring you a clear schematic of the mechanism of action of liposomal ozonized oil.

Source: Treatment of Glaucoma 24. 3. 2023

News Alleviation of Asthma and Chronic Sinusitis Symptoms in Patients with Atopic Dermatitis Thanks to Dupilumab

An analysis of results in adult patients with moderate to severe atopic dermatitis, who also had asthma and/or chronic rhinosinusitis, investigated how clinically and statistically significant the benefit of dupilumab is for all these 3 conditions in comparison with a placebo.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 12. 8. 2021

News Continuation of Treatment with Tofacitinib in Rheumatoid Arthritis –⁠ Real-World Clinical Practice Data

The oral Janus kinase inhibitor tofacitinib has been extensively tested in patients with rheumatoid arthritis in numerous international randomized clinical trials. According to a recently published review summarizing retrospective, prospective, and observational studies from real-world clinical practice published in 2018–2020, the treatment duration with tofacitinib is comparable to that with biological disease-modifying drugs.

Source: Arthritis 29. 3. 2022

News Urgent Administration of Romiplostim in Life-Threatening Bleeding Associated with ITP

Recommendations for the care of acute, especially major bleeding in individuals with severe immune thrombocytopenia (ITP) are not entirely clear. Various methods (steroid boluses, intravenous immunoglobulins, platelet transfusions, etc.) can be used to quickly increase platelet count, but the response may not always be straightforward. Recently, reports have been published regarding the use of thrombopoietin receptor agonists (TPO-RAs) specifically aimed at rapidly increasing platelet count. The use of romiplostim in patients with ITP and intracranial hemorrhage is illustrated by the following case studies.

Source: Immune Thrombocytopenia 10. 8. 2022

News Consolidation therapy with brentuximab vedotin after autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma

At the 12th International Symposium on Hodgkin Lymphoma (ISHL), held in October 2022 in Cologne, results of a Czech study evaluating the efficacy and safety of consolidation therapy with brentuximab vedotin in patients after autologous stem cell transplantation were presented.

Source: Hematologic Malignancies 22. 12. 2022

News Candesartan Could Ameliorate the Cytokine Storm in COVID-19 Infection

Scientists from Bethesda, USA, experimentally found the upregulation of the same genes during COVID-19 infection as with the action of glutamate (simulating aging and Alzheimer's disease) and the normalization of their expression by candesartan. Considering that many of these genes are involved in the cytokine storm in COVID-19, the mentioned results support the hypothesis that sartans −⁠ or at least candesartan −⁠ could mitigate the cytokine storm in patients with severe COVID-19.

Source: Sartans in the Treatment of Hypertension 27. 1. 2021